Neumora Therapeutics
NMRA | NASDAQ
$0.49
-$0.01 (-2.64%)
At close: Nov 9, 2026, 4:00 PM ET
-2.64%
(1D)No price chart data available for 1D timeframe.
Rating
33
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #725/1025 (Top 71%)
Key Statistics
Market Data
Market Cap $91.3M
1D Range
0.48 0.56
52W Range
0.35 3.59
Valuation (TTM)
PE -0.40
PB 2.05
EV/EBITDA 0.12
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $4.50
Cash Flow
FCF Yield -197.7%
SBC Adj. FCF Yield -228.4%
SBC Impact -15.5%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 16.6% |
3.4%
FCF 3Y | 5Y 4.7% |
-14.0%
Returns
ROA -169.9%
ROE -242.3%
ROIC -216.1%
Financial Health
Net Cash
$116.49M
Current Ratio 4.50
Interest Coverage -32.71
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerat...
Sector Healthcare
Industry Biotechnology
Employees 63
IPO Date Sep 15, 2023
Website www.neumoratx.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
7
Consensus
Buy
Price Target
$4.50
Upside
+818.37%
Buy (6)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove NMRA